Search Within

Steven M Horwitz

Formats
  1. Meeting Abstract (374)
  2. Journal Article (248)
  3. Review (13)
  4. Guidelines (11)
  5. Research Letter (9)
  6. Book Section (6)
  7. Correspondence (5)
  8. Editorial (4)
  9. Miscellaneous (1)
Groups
  1. Center for Hematologic Malignancies (671)
  2. Department of Medicine (671)
  3. Hematologic Malignancies, Division of (671)
  4. Lymphoma (671)
  5. Population Sciences Research Program (671)
  6. Survivorship Research (173)

More Groups

People
  1. Alison Moskowitz (235)
  2. Andrew Zelenetz (169)
  3. Paul Hamlin (140)
  4. Ariela Noy (139)
  5. David Straus (122)
  6. Maria Palomba (112)

More People

Years
  1. 2025 (18)
  2. 2024 (51)
  3. 2023 (41)
  4. 2022 (34)
  5. 2021 (53)
  6. 2020 (52)

More Years

Publications
  1. Blood (255)
  2. Journal of Clinical Oncology (64)
  3. Hematological Oncology (38)
  4. Blood Advances (19)
  5. Leukemia and Lymphoma (19)
  6. Annals of Oncology (18)

More Publications

Publishers
  1. American Society of Hematology (277)
  2. American Society of Clinical Oncology (65)
  3. Wiley Blackwell (55)
  4. Elsevier Inc. (34)
  5. Oxford University Press (25)
  6. Taylor & Francis Group (23)

More Publishers

Results (671)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • First‐in‐human study of the EZH1 and EZH2 dual inhibitor valemetostat tosylate (DS‐3201b) in patients with relapsed or refractory non‐Hodgkin lymphomas
    Meeting Abstract

    Ishitsuka, K.; Izutsu, K.; Maruyama, D.; Makita, S.; Jacobsen, E. D.; Horwitz, S.; Kusumoto, S.; Allen, P.; Porcu, P.; Imaizumi, Y.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • A phase II trial of reduced dose brentuximab vedotin for cutaneous T‐cell lymphomas
    Meeting Abstract

    Khan, N.; Noor, S.; Geller, S.; Khodadoust, M. S.; Kheterpal, M.; Hancock, H.; Davey, T.; Ryu, S.; Perez, L.; Lares, A.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • The combination of duvelisib and romidepsin (DR) is highly active against relapsed/refractory peripheral T‐cell lymphoma with low rates of transaminitis: Final results
    Meeting Abstract

    Horwitz, S. M.; Moskowitz, A. J.; Mehta‐Shah, N.; Jacobsen, E. D.; Khodadoust, M. S.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Myskowski, P.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Preliminary activity of devimistat (CPI 613) in patients with relapsed or refractory Burkitt lymphoma/leukemia
    Meeting Abstract

    Nikolaenko, L.; Pardee, T. S.; Steiner, R.; Abramson, J. S.; Horwitz, S.; Matasar, M.; Owens, C.; Rodriguez-Rivera, I.; Straus, D.; Luther, S.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Frontline brentuximab vedotin and CHP (A+CHP) in patients with peripheral T‐cell lymphoma with less than 10% CD30 expression (SGN35‐032, trial in progress)
    Meeting Abstract

    Jagadeesh, D.; Knowles, S.; Horwitz, S. M.
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Clinical outcomes and the role of observation in early‐stage follicular lymphoma
    Meeting Abstract

    Sha, F.; Okwali, M.; Alperovich, A.; Caron, P. C.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; Kumar, A.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Camidanlumab tesirine in patients with relapsed or refractory lymphoma: A phase 1, open-label, multicentre, dose-escalation, dose-expansion study
    Journal Article

    Hamadani, M.; Collins, G. P.; Caimi, P. F.; Samaniego, F.; Spira, A.; Davies, A.; Radford, J.; Menne, T.; Karnad, A.; Zain, J. M.; more...
    The Lancet Haematology (2021)

    Fulltext@MSK | Save
  • Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse
    Journal Article

    Bobillo, S.; Joffe, E.; Sermer, D.; Mondello, P.; Ghione, P.; Caron, P. C.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Kumar, A.; more...
    Blood Cancer Journal (2021)

    Fulltext@MSK | Save
  • ECHELON-2 (NCT01777152), a randomized, double-blind, phase 3 study of brentuximab vedotin plus cyclophosphamide doxorubicin and prednisone versus cyclophosphamide, doxorubicin, vincristine and prednisone in previously untreated patients with CD30-positive peripheral T-cell lymphoma: 5-year results
    Meeting Abstract

    Illidge, T.; Horwitz, S. M.; O'Connor, O. A.; Pro, B.; Iyer, S. P.; Advani, R.; Bartlett, N. L.; Christensen, J. H.; Morschhauser, F.; Domingo-Domenech, E.; more...
    British Journal of Haematology (2021)

    Fulltext@MSK | Save
  • Molecularly targeted therapies for relapsed and refractory peripheral T-cell lymphomas
    Review

    Epstein-Peterson, Z. D.; Horwitz, S. M.
    Seminars in Hematology (2021)

    Fulltext@MSK | Save